Mercurity Fintech Holding Inc. Announced Third Private Investment In Public Equity Financing Of $5 Million
Round Type
Venture
BostonBiotechnologyHealth CareTherapeuticsDescription
Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group powered by blockchain technology, today announced that on December 23, 2022, in connection with its private investment in public equity financing (the “PIPE”), it entered into a Securities Purchase Agreement (the “SPA”) with an accredited non-U.S. investor to offer and sell the Company’s units, each consisting of one ordinary share and three Warrants (each, a “Warrant” and collectively, the “Warrants”) for total gross proceeds of $5 million (the “Proceeds”). The closing of this third PIPE financing together with the consummation of the first and second PIPE financing would yield total gross proceeds of $13.15 million invested in the Company’s shares and warrants by third parties in the second half of 2022
Quick answer
Cue Biopharma raised an undisclosed amount in a funding round, dated December 27, 2022. Cue Biopharma is based in Boston, Massachusetts, United States.
- How much did Cue Biopharma raise?
- Cue Biopharma raised an undisclosed amount in a funding round on December 27, 2022.
- What does Cue Biopharma do?
- Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease.
- Where is Cue Biopharma based and how big is it?
- Cue Biopharma is based in Boston, Massachusetts, United States. Fundz records about 29 employees.
- Who are the decision-makers at Cue Biopharma?
- Fundz holds 2 contacts at Cue Biopharma, including the Biotech CEO | Board Member & Chairman| LifeScience Advisor. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Cue Biopharma that raised within 45 days of this round, from Fundz verified event records.
- Chroma Medicine raised $135M on February 8, 2023.
- CUREMARK LLC raised $1.3M (Seed) on January 30, 2023.
- Grey Wolf Therapeutics raised $49M (Funding Round) on January 27, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- ADARx Pharmaceuticals, Inc. raised $46M on January 26, 2023.
- HBM Alpha Therapeutics raised an undisclosed amount (Seed) on January 26, 2023.
Who to call at Cue Biopharma, and when
A new round usually means Cue Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cue Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cue Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cue Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cue Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cue Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.